[en] BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral ibandronate has been developed to overcome this problem. OBJECTIVE: To confirm the 1 year results and provide more extensive safety and tolerability information for once-monthly dosing by a 2 year analysis. METHODS: MOBILE, a randomised, phase III, non-inferiority study, compared the efficacy and safety of once-monthly ibandronate with daily ibandronate, which has previously been shown to reduce vertebral fracture risk in comparison with placebo. RESULTS: 1609 postmenopausal women were randomised. Substantial increases in lumbar spine bone mineral density (BMD) were seen in all treatment arms: 5.0%, 5.3%, 5.6%, and 6.6% in the daily and once-monthly groups (50 + 50 mg, 100 mg, and 150 mg), respectively. It was confirmed that all once-monthly regimens were at least as effective as daily treatment, and in addition, 150 mg was found to be better (p<0.001). Substantial increases in proximal femur (total hip, femoral neck, trochanter) BMD were seen; 150 mg produced the most pronounced effect (p<0.05 versus daily treatment). Independent of the regimen, most participants (70.5-93.5%) achieved increases above baseline in lumbar spine or total hip BMD, or both. Pronounced decreases in the biochemical marker of bone resorption, sCTX, observed in all arms after 3 months, were maintained throughout. The 150 mg regimen consistently produced greater increases in BMD and sCTX suppression than the 100 mg and daily regimens. Ibandronate was well tolerated, with a similar incidence of adverse events across groups. CONCLUSIONS: Once-monthly oral ibandronate is at least as effective and well tolerated as daily treatment. Once-monthly administration may be more convenient for patients and improve therapeutic adherence, thereby optimising outcomes.
Disciplines :
Rheumatology
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Melton U, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-10.
International Osteoporosis Foundation. Osteoporosis in the European community: action plan. International Osteoporosis Foundation, 2003. Available from, http://www.osteofound.org/advocacy_policy/eu_policy_project/pdf/ action_plan_03_e.pdf (accessed 12 January 2006).
Melton U. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003;18:1139-41.
Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.
Delmas PD, Recker RR, Chesnut CH, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8.
Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8.
Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.
Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002;(2):CD000011.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
Åkesson K, Beusterien K, Hebborn A, Kline Leidy N, Simon J. Patient preference for once-monthly over once-weekly bisphosphonate treatment [abstract]. Osteoporos Int 2005;16(suppl 3):S83.
Cramer JA, Amonkar MM, Hebborn A, Suppapanya N. Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? [abstract]. J Bone Miner Res 2004;19(suppl 1):S448.
Ettinger MP, Gallagher R, Amonkar M, Smith JC, MacCosbe PE. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate [abstract]. Arthritis Rheum 2004;50(suppl):S513.
Bartl R, Goette S, Hadji P, Hammerschmidt T. Persistence and compliance with daily- and weekly-administered bisphosphonates in German women with osteoporosis [abstract]. Osteoporos Int 2005;16(suppl 3):S45.
Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8.
Eastell R, Garnero P, Vrijens L, van de Langerijt L, Pols HAP, Ringe JD, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the Impact Study [abstract]. Calcif Tissue Int 2003;72:P-297.
Sebaldt RJ, Shane LG, Pham BZ, Cook R, Thabane L, Petrie A, et al. Longer-term effectiveness outcomes of non-compliance and non-persistence with daily-regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care [abstract]. Osteoporos Int 2004;15(suppl 1):S107.
Mühlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6:1003-11.
Bauss F, Russell GG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004;15:423-33.
Reginster JY, Wilson KM, Dumont E, Bonvoisin B, Barrett J. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metab 2005;90:5018-24.
Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE Study. J Bone Miner Res 2005;20: 1315-22.
Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-6.
Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-92.
Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use. The OFELY study. J Bone Miner Res 2003;18:1789-94.
ICH. ICH harmonized tripartite guideline. Statistical principles for clinical trials. Statist Med 1999;18:1905-42.
Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004;34:599-604.
Website. Alendronate prescribing information. http://www.fosamax.com (accessed 12 January 2006).
Wensite. Risedronate prescribing information. http://www.actonel.com (accessed 12 January 2006).
